Enecadin

Enecadin

SCHEMBL678822

Cc1nc(OCCCCCN2CCCCC2)cc(-c2ccc(F)cc2)n1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.55
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 1/20 0.53
KCNH2 Q12809 2/20 0.50
ACP1 P24666 1/20 0.46
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HRH4 Q9H3N8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4602839 1.00 HRH3 (0.55) HRH3MEN1KMT2ALMNAHTT
Enecadin SCHEMBL29406882 0.99 HRH3 (0.54) HRH3MEN1KMT2ALMNAHTT
Enecadin SCHEMBL562985 0.99 HRH3 (0.54) HRH3MEN1KMT2ALMNAHTT
Enecadin SCHEMBL5420925 0.99 HRH3 (0.54) HRH3MEN1KMT2ALMNAHTT
Hydrochloric Acid SCHEMBL6587974 0.99 HRH3 (0.54) HRH3MEN1KMT2ALMNAHTT
Enecadin SCHEMBL5420920 0.99 HRH3 (0.54) HRH3MEN1KMT2ALMNAHTT
SCHEMBL4603419 0.99 HRH3 (0.53) HRH3MEN1KMT2ALMNAHTT
Hydrochloric Acid SCHEMBL6593396 0.98 HRH3 (0.52) HRH3MEN1KMT2ALMNAHTT
Hydrochloric Acid SCHEMBL6586710 0.94 KCNH2 (0.53) HRH3KCNH2ACP1
Hydrochloric Acid SCHEMBL6587345 0.91 KCNH2 (0.47) KCNH2ACP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339445-A1 Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke UNIV EMORY (US) 2025-11-06 US claimed
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE HOTH THERAPEUTICS, INC. 2025-01-30 US claimed
EP-4236961-A1 MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR TREATING PANCREATITIS, GLIOBLASTOMA, SARCOPENIA AND STROKE Emory University (US) 2023-09-06 EP claimed
WO-2022094435-A1 MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR TREATING PANCREATITIS, GLIOBLASTOMA, SARCOPENIA AND STROKE EMORY UNIVERSITY (US) 2022-05-05 WO claimed
EP-1941879-A1 Neuroprotective agent for the treatment of neuronal damage PAION Deutschland GmbH (DE) 2008-07-09 EP claimed
US-20070021451-A1 Method for preventing or treating neurologic damage after spinal cord injury HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) 2007-01-25 US claimed
US-7091206-B2 Process for producing pyrimidine derivative and intermediate thereof NIPPON SHINYAKU CO., LTD (JP) 2006-08-15 US claimed
EP-1318146-B1 PROCESS FOR PRODUCING PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF NIPPON SHINYAKU CO LTD (JP) 2005-02-23 EP claimed
EP-0781766-B1 HETEROCYCLIC DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO LTD (JP) 2004-03-31 EP claimed
US-20040023985-A1 Process for producing pyrimidine derivative and intermediate thereof NIPPON SHINYAKU CO., LTD. (JP) 2004-02-05 US claimed
EP-1318146-A1 PROCESS FOR PRODUCING PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF Nippon Shinyaku Co., Ltd. (JP) 2003-06-11 EP claimed
US-5945426-A PREVENT NEURONAL DEATH NIPPON SHINYAKU CO., LTD. (JP) 1999-08-31 US claimed
EP-0781766-A1 HETEROCYCLIC DERIVATIVE AND MEDICINE NIPPON SHINYAKU COMPANY, LIMITED (JP) 1997-07-02 EP claimed
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS KARUNA THERAPEUTICS INC (US) 2026-02-26 US disclosed
US-12509451-B2 Heteroaryl amide inhibitors of CD38 NAPA THERAPEUTICS LIMITED (IM) 2025-12-30 US disclosed
US-20250339445-A1 Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke UNIV EMORY (US) 2025-11-06 US disclosed
EP-1108430-A1 CALCIUM CHANNEL ANTAGONISTS Nippon Shinyaku Co., Ltd. (JP) 2001-06-20 EP disclosed
US-6191149-B1 DRUG FOR CEREBROVASCULAR DISEASE NIPPON SHINYAKU, CO., LTD. (JP) 2001-02-20 US disclosed
US-5945426-A PREVENT NEURONAL DEATH NIPPON SHINYAKU CO., LTD. (JP) 1999-08-31 US disclosed
EP-0781766-A1 HETEROCYCLIC DERIVATIVE AND MEDICINE NIPPON SHINYAKU COMPANY, LIMITED (JP) 1997-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339445-A1 Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke RXRA, RXRG, RXRB HRH3 2963/4885MEN1 3085/4885KMT2A 3736/4885
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE TACR1, ACHE, TACR2 HRH3 130/4885MEN1 2886/4885KMT2A 1550/4885
US-20070021451-A1 Method for preventing or treating neurologic damage after spinal cord injury SMN1; SMN2, AQP4, GAP43 HRH3 3019/4885MEN1 4187/4885KMT2A 3596/4885
US-12509451-B2 Heteroaryl amide inhibitors of CD38 CD38, FCGRT, BCL6 HRH3 2426/4885MEN1 3066/4885KMT2A 1927/4885
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CHRM3, CHRM2, CHRM1 HRH3 41/4885MEN1 3715/4885KMT2A 4023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.